(Q39404720)

11 September 2017

Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells (English)

1 reference

11 September 2017

1 reference

T Martinsson

8

0 references

author name string

C Schönherr

1

1 reference

11 September 2017

K Ruuth

2

1 reference

11 September 2017

S Kamaraj

3

1 reference

11 September 2017

C-L Wang

4

1 reference

11 September 2017

H-L Yang

5

1 reference

11 September 2017

V Combaret

6

1 reference

11 September 2017

A Djos

7

1 reference

11 September 2017

J G Christensen

9

1 reference

11 September 2017

R H Palmer

10

1 reference

11 September 2017

B Hallberg

11

1 reference

11 September 2017

language of work or name

English

0 references

publication date

30 January 2012

1 reference

11 September 2017

1 reference

11 September 2017

31

1 reference

11 September 2017

5193-5200

1 reference

11 September 2017

50

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2012.12

11 September 2017

0 references

cites work

Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Neuroblastoma: biological insights into a clinical enigma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Overall genomic pattern is a predictor of outcome in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

ArrayCGH-based classification of neuroblastoma into genomic subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Oncogenic mutations of ALK kinase in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Activating mutations in ALK provide a therapeutic target in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Identification of ALK as a major familial neuroblastoma predisposition gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Anaplastic lymphoma kinase: signalling in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Modulation of N-myc expression alters the invasiveness of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Targeted expression of MYCN causes neuroblastoma in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Myc proteins as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

The Axin1 scaffold protein promotes formation of a degradation complex for c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Protein kinase signaling networks in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Crizotinib--latest champion in the cancer wars?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Sensitive detection of numerical and structural aberrations of chromosome 1 in neuroblastoma by interphase fluorescence in situ hybridization. Comparison with restriction fragment length polymorphism and conventional cytogenetic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Combined 24-color karyotyping and comparative genomic hybridization analysis indicates predominant rearrangements of early replicating chromosome regions in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Proteasome inhibitors: valuable new tools for cell biologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Anaplastic lymphoma kinase expression in neuroblastomas and its relationship with genetic, prognostic, and predictive factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

The ligand Jelly Belly (Jeb) activates the Drosophila Alk RTK to drive PC12 cell differentiation, but is unable to activate the mouse ALK RTK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

High incidence of DNA mutations and gene amplifications of theALKgene in advanced sporadic neuroblastoma tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

MYCN oncogene and angiogenesis: down-regulation of endothelial growth inhibitors in human neuroblastoma cells. Purification, structural, and functional characterization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

ALK and NSCLC: Targeted therapy with ALK inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

31 March 2020

Identifiers

DOI

10.1038/ONC.2012.12

1 reference

11 September 2017

1 reference